Amarin Corporation (AMRN), recently announced Q3 earnings with a beat on EPS and revenue. This was another record quarter for Amarin, who pulled in $112.4M in revenue while limiting their net loss to $3.5M. This record quarter was fueled by Vascepa's growth in number of scripts and number of prescribers. Now, Amarin has to return their attention to the pending clash with the FDA at Vascepa's FDA Advisory Committee "AdCom" meeting on November 14th. The company will have to defend Vascepa's sNDA against the FDA in front of the committee and hopefully convince